G1SecL05: Difference between revisions
mNo edit summary |
|||
| Line 4: | Line 4: | ||
= Table of Contents= | = Table of Contents= | ||
''' | *'''#. Background ''' | ||
''' | *'''#. Development of the recombinant vaccine | ||
''' | *'''#. Introduction to the LA-2 fab complex | ||
''' | *'''#. Binding affinitity and interactions in the LA-2 fab complex''' | ||
''' | *'''#. Structural Defects in the vaccine''' | ||
*'''#. Discussion''' | |||
'''Background''' | '''Background''' | ||
| Line 14: | Line 15: | ||
Lyme disease, discovered in 1975, is a vector- borne disease caused by the inoculation of spirochete borrelia into the skin by members of hard bodied ticks of the family Ixodidae. Symptoms include arthritis at major joints, neurological problems such as reduced memory and poor ability to concentrate, and characteristic lesions erythema migans, more commonly known as the bull’s eye rash. A major outer surface membrane protein of Borrelia, ospA, plays a key role in immunity against Lyme disease through its binding to the antibody LA-2 fab. | Lyme disease, discovered in 1975, is a vector- borne disease caused by the inoculation of spirochete borrelia into the skin by members of hard bodied ticks of the family Ixodidae. Symptoms include arthritis at major joints, neurological problems such as reduced memory and poor ability to concentrate, and characteristic lesions erythema migans, more commonly known as the bull’s eye rash. A major outer surface membrane protein of Borrelia, ospA, plays a key role in immunity against Lyme disease through its binding to the antibody LA-2 fab. | ||
''' Development of the recombinant vaccine ''' | |||
<Structure load='1fj1' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | <Structure load='1fj1' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | ||